Partner Courtenay Brinckerhoff was quoted in a BioWorld article, “USPTO rule change could end PTAB’s reputation as a patent killer,” about a proposed change in the rules that would align the standard the Patent Trial and Appeal Board uses in inter partes review proceedings with that of the courts.
Brinckerhoff said PTAB currently uses the “broadest reasonable interpretation” standard, which some patent holders claim is too broad and not very reasonable.
She also said PTAB’s broader reading opens a patent claim to more prior art than the courts’ narrow interpretation, meaning that a claim that has stood up under court scrutiny could still be struck down by PTAB. By restricting the prior art that would be considered, she said, the proposed rule change could lead PTAB to validate more claims.
Brinckerhoff said PTAB currently uses the “broadest reasonable interpretation” standard, which some patent holders claim is too broad and not very reasonable.
She also said PTAB’s broader reading opens a patent claim to more prior art than the courts’ narrow interpretation, meaning that a claim that has stood up under court scrutiny could still be struck down by PTAB. By restricting the prior art that would be considered, she said, the proposed rule change could lead PTAB to validate more claims.
People
Related News
March 13, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 10, 2026
In the News
Aaron Maguregui Shares Insights on Shadow AI Risks in Health Care
Foley & Lardner LLP partner Aaron Maguregui was quoted in the Part B News article, “Do you need AI policy? Experts suggest guardrails as 'shadow AI' spreads,” discussing the emerging risks of unsanctioned 'shadow AI' use by clinicians and the need to establish robust AI governance.